- Home
- NMP vs ELTX Comparison
NMP vs ELTX Comparison
Compare NMP & ELTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMP
- ELTX
- Stock Information
- Founded
- NMP 2024
- ELTX 2011
- Country
- NMP United States
- ELTX United States
- Employees
- NMP N/A
- ELTX N/A
- Industry
- NMP Blank Checks
- ELTX Biotechnology: Pharmaceutical Preparations
- Sector
- NMP Finance
- ELTX Health Care
- Exchange
- NMP Nasdaq
- ELTX Nasdaq
- Market Cap
- NMP 159.9M
- ELTX 158.5M
- IPO Year
- NMP 2025
- ELTX N/A
- Fundamental
- Price
- NMP $10.04
- ELTX $9.20
- Analyst Decision
- NMP
- ELTX Strong Buy
- Analyst Count
- NMP 0
- ELTX 1
- Target Price
- NMP N/A
- ELTX $13.00
- AVG Volume (30 Days)
- NMP 55.9K
- ELTX 106.8K
- Earning Date
- NMP 01-01-0001
- ELTX 11-13-2025
- Dividend Yield
- NMP N/A
- ELTX N/A
- EPS Growth
- NMP N/A
- ELTX N/A
- EPS
- NMP N/A
- ELTX N/A
- Revenue
- NMP N/A
- ELTX N/A
- Revenue This Year
- NMP N/A
- ELTX N/A
- Revenue Next Year
- NMP N/A
- ELTX N/A
- P/E Ratio
- NMP N/A
- ELTX N/A
- Revenue Growth
- NMP N/A
- ELTX N/A
- 52 Week Low
- NMP $9.90
- ELTX $4.60
- 52 Week High
- NMP $10.07
- ELTX $12.62
- Technical
- Relative Strength Index (RSI)
- NMP N/A
- ELTX 41.87
- Support Level
- NMP N/A
- ELTX $8.60
- Resistance Level
- NMP N/A
- ELTX $9.45
- Average True Range (ATR)
- NMP 0.00
- ELTX 0.48
- MACD
- NMP 0.00
- ELTX 0.03
- Stochastic Oscillator
- NMP 0.00
- ELTX 41.03
About NMP NMP Acquisition Corp. Class A Ordinary Shares
NMP Acquisition Corp is a blank check company.
About ELTX Elicio Therapeutics Inc.
Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking.